Trastuzumab (T) plus vinorelbine (VNR) as first combination in Her-2 overexpressing patients with metastatic breast cancer

Głogowska, Iwona; Sienkiewicz-Kozłowska, Renata; Bauer-Kosinska, B.; Jaczewska, S.

doi:10.1200/jco.2004.22.90140.3165

Search citation statements

Order By: Relevance

Paper Sections

Select...

Trastuzumab Plus Vinorelbine1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1) [14][15][16][17][18][19][20][21][22]. In general, firstline therapy produced higher response rates.…”

Section: Trastuzumab Plus Vinorelbinementioning

confidence: 99%

HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy

Jackisch

2006

The Oncologist

View full text Add to dashboard Cite

Trastuzumab with a taxane as first-line therapy is now the standard of care for patients with human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer (MBC). The search for additional and more effective trastuzumab-based therapies continues. Novel combinations of trastuzumab with chemotherapeutic agents, including vinorelbine, gemcitabine, and capecitabine, and hormonal therapy agents, such as tamoxifen and aromatase inhibitors, are currently under investigation in clinical trials. Available data suggest these combinations will provide additional treatment options that may ultimately lead to better outcomes for patients with HER-2-positive MBC. Evidence is growing for the use of trastuzumab treatment beyond disease progression and retreatment after (neo)adjuvant relapse is being explored to assist in clinical decision making. Already, the use of trastuzumab in the metastatic setting has changed HER-2-positive status from a marker of poor prognosis to one of better overall outcome, and ongoing studies should expand further the treatment options for patients with HER-2-positive MBC.

show abstract

“…1) [14][15][16][17][18][19][20][21][22]. In general, firstline therapy produced higher response rates.…”

Section: Trastuzumab Plus Vinorelbinementioning

confidence: 99%